header logo image


Page 752«..1020..751752753754..760770..»

Human Longevity Announces the Acquisition of DoctorsForMe – Yahoo Finance

January 18th, 2020 8:41 pm

Clients now have access to Massachusetts General Hospital physician network through DoctorsForMe to help treat disease and support long-term health

Human Longevity, Inc., an innovator in providing data-driven health intelligence and precision health to physicians and patients, announced today the acquisition of DoctorsForMe, Inc. The acquisition now allows clients of Human Longevity to access world-class physicians and services of Mass General, well trusted by patients worldwide as one of the best hospitals in the world.

David Karow, MD, PhD, President and Chief Innovation Officer of Human Longevity, commented, "DoctorsForMe uses Big Data and AI technologies to match a patient with a doctor that perfectly matches the patients specific need. The acquisition enables Human Longevity to provide a complete health intelligence solution for our clients from early disease detection to personalized treatment, all with the goal of living a longer, healthier life."

ABOUT HUMAN LONGEVITY

Human Longevity provides unparalleled, precision health analytics to individuals through the Health Nucleus in La Jolla, CA. The Health Nucleus provides an assessment of current and future risk for cardiac, oncologic, metabolic and cognitive diseases and conditions. This is provided via a multi-modal approach, integrating data from an individuals whole genome, brain and body imaging via MRI, cardiac CT calcium scan, metabolic tests and more, using machine learning and artificial intelligence.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005207/en/

Contacts

Debbie Feinberg, VP of MarketingHuman Longevity, Inc.858-864-1058dfeinberg@humanlongevity.com

See more here:
Human Longevity Announces the Acquisition of DoctorsForMe - Yahoo Finance

Read More...

Learn the longevity secrets of this Chinese city which houses over 1,200 centenarians – The Tribune

January 18th, 2020 8:41 pm

Nantong, January 13

A towering bronze sculpture of the God of Longevity watches over the city of Rugao in east Chinas Nantong, which is home to an astounding over 1,200 centenarians.

The imposing statue which stands in the garden of longevity is said to artistically depict Chinese deity Shouxing, a bearded old man with a high brow, carrying a crooked staff in one hand, and holding the peach of immortality in his other hand.

The local government prides itself on the large count of people, aged over 100 years, living in Nantong - a port city, attributing it also to healthy habits, fresh air and beauty of nature, blessed by the Yangtze, the mother river of China.

According to senior officials in the Nantong administration, the prefecture-level city, located about 120-kilometer from Shanghai, had 1,205 centenarians till November last year.

Perhaps, the most famous region in east China for being the abode of centenarians is Rugao, a county-level city in Nantong in Jiangsu province.

The number of centenarians in Rugao had reached 524 by January 1, an increase of 84 over the previous year, according to a recent report by the state-run China Daily, quoting the local civil affairs bureau.

The report published on Nantong administrations website also said that there were 16 centenarians aged 105 or above.

Rugao currently has a permanent population of 1.42 million, with 3,91,700 aged 60 and above, 65,200 aged 80 and above, and 9,200 aged 90 and above.

These numbers are much higher than the provincial and national averages, it said.

Yang Deying, 110, is the oldest centenarian in Rugao.

She enjoys her life now with his family and spends time with her great-grand son too. The whole family is having a very wonder life, according to an official at the China Daily.

Yang can still hear, see things, this is an ideal life of someone whose age is more than 100 years. One of her sons, and a daughter-in-law take care of her every day. She has other children too, the official said.

The state-run English daily in partnership with the Jiangsu local government, recently organised a visit to the province for 15 journalists from several countries, who had also visited elderly care centres in Nantong and two other cities.

In a community park in the heart of Nantong in Hongqiao subdistrict, old men can be seen practising Tai Chi (shadow boxing) or reading newspapers, while old women in group perform dance routines inside the elderly-care service centre, neighbouring it.

The subdistrict in Chongchuan district has 35,000 families living with a population of around 100,000, according to officials.

Nearly 18,000 old people live in this area. Through our elderly-care centre, we provide food and other needed services to a section of those people. Medical services are also available at the centre, besides recreational facilities to make them feel engaged. Many volunteers also visit disabled elderly at home to take care of them, a senior official said.

Many of their children are working, so these old people come here and interact with each other, eat food and play games to keep themselves fit and occupied, he said.

Healthy diet and sleeping habits, as well as a convivial environment, are believed to have contributed to longevity in Rugao, earning it the moniker of city of longevity.

We want our Nantong to be a world-class city. Work going on expanding the urban infrastructure and a new bridge being built to connect faster to Shanghai. But, Nantong is also a city having fresh air and the blessing of mother river Yangtze, so many people live for over 100 years, a senior official of Nantong administration said.

The historic city of Nantong is home to several old Chinese gardens, Langshan Mountain National Forest Park, and various architectural heritage.

Located on the confluence of Yangtze River, Yellow Sea and East China Sea, the convergence lends Nantong the sobriquet of Great Pearl from Yangtze River and Sea.

In this salubrious environment, it is not uncommon in Rugao to see several centenarian couples celebrating golden jubilee of their wedding anniversaries, grandparents celebrating birthdays after crossing 100-year mark.

China has witnessed a rise in peoples average life expectancy over the years, from 74.83 years in 2010 to 76.7 years in 2017, according to the National Health Commission.

The average life expectancy for Chinese will go up to 77 years by 2020, one year more than the figure in 2015, the health authorities in Beijing had earlier said.

Chinese view long life as a special blessing and on birthdays and other special occasions for elders, visitors bow before the statue of the God of Longevity, to seek blessings, locals said.

Nantong was named the first longevity capital of the world by the International Society of Natural Medicine and the World Longlife Township Accreditation Committee, according to a 2019 Chinese government publication on the city. PTI

Read the original here:
Learn the longevity secrets of this Chinese city which houses over 1,200 centenarians - The Tribune

Read More...

New Study Reveals Foods Linked To Longer Life Expectancy – International Business Times

January 18th, 2020 8:41 pm

KEY POINTS

A study conducted by Harvard School of Public Health researchers indicates that eating spicy foods could help improve longevity. Their findings, which were published in the British Medical Journal in 2005, state that people who consume spicy foods daily have a 14% lower risk of death. This is in comparison to people who consumed spicy foods only once a week.

China Population

The researchers analyzed the diet and health information of nearly 500,000 people living in China from 2004 to 2008, then followed them up a couple of years later. Since the study was observational in nature, it did not show if spicy foods help people live longer. It revealed, however, that people who consumed spicy food regularly were less likely to have died within the study period compared to those who consumed less spicy food.

Dr. Lu Qi, the author of the study, stated that evidence from many other studies indicate the bioactive ingredients found in spicy foods like capsaicin reduces bad cholesterol. It also minimizes triglycerides and helps in improving inflammation.

Foods that contain dried and fresh chili peppers have shown the most potential.A study that was published in PLoS ONE, a medical journal, also linked the spice with a 13% lower risk of death. spicy food and longevity Photo: englishlikeanative - Pixabay

The Study

Using information made available by the National Health and Examination Survey, the University of Vermont scientists analyzed the diet patterns of more than 16,000 American adults. The scientists asked the question of how often did these adults eat or consume red hot chili peppers. They noted that those who reported eating any hot peppers during the previous months had lower mortality rates, after making adjustments for other factors, for 18 years.

Among the benefits of capsaicin is weight loss. There is evidence that indicates it promotes weight loss by moderating appetite and increasing the bodys ability to burn fat. Studies also reveal ten grams of red chili pepper can considerably boost fat burning in both males and females.

Researchers also found that capsaicin can minimize your calorie intake. The study, which involved 24 participants, showed that those who regularly consume chili found they were able to reduce their calorie intake.

More:
New Study Reveals Foods Linked To Longer Life Expectancy - International Business Times

Read More...

Breaking the Small Business Owners Curse: Hiring for Longevity – The Good Men Project

January 18th, 2020 8:41 pm

As a business owner, Ive frequently struggled with hiring good people and ensuring they last. Im sure a lot of other people also struggle with it. Thats why I wanted to write this article.

It doesnt help that we can sometimes give up early in the hiring process either since we get so frustrated. I did that when I first started out and was ready to tear my hair out when I would see more money going out the door on training new hires that didnt work out. Often, when that happens, you spend even less time on reworking the hiring system. I get it. You might feel like: whats the point? Im doomed to sort through crappy people forever.

In my case, I came from the field and believed that as long as I could work hard as a tech, I could scale and last in the marketplace. Maybe you can relate? Maybe you apply this same logic to hiring? Heres the catch: using what worked when you were a startup is exactly why you cant hold onto your peoplewhy you threaten your potential to grow.

If you have aspirations for a business that is more than just you, then youre going to need to leverage other peoples time and energy. Youre going to have to train individuals in the methodologies, systems, and processes you use that make you great.

But dont worry, because I can tell you what you need to knowand what you already knowif you read my last article on defining your core values. Thats the secret. To make your people stick, You need to be clear on your core values. This piece of the foundation is paramount if you want to be successful in the long-term.

If your core values arent clear, you have the possibility or potential to allow infectious people into your organization. And when I say infectious, I mean people who dont align with you or your purpose. But you wont know this from the jump. They might be a skilled person and from the outside seem like a logical fit. But then youll find out theyll always show up late or dont speak nicely to customers.

Id rather have a guy with a lower skill set who is coachable and can be trained and molded into the correct technician that we want. As long as the core values are in alignment and are the underlying foundation within that persons life, theyre going to align with Top Class.

Even though this is a little bit of a different approach when it comes to onboarding and training people, its definitely made a significant difference in our business.

A couple of years ago, we had three really shitty hires back to back to back in a short period. We thought the timing was perfect because we had a big project coming up, and that allowed a couple of weeks leeway to get these guys up to speed. They would know what they were doing and be trustworthy. We felt good about hiring them initially. But in less than 90 days, all three people had been fired, or theyd quit.

What I learned is that if you want to prevent what we went through with these hires, then you need to identify your core values and leverage them properly.

If youre still not convinced, Google employee cost calculators; youll see the numbers are absolutely disgusting. Check out what it costs in advertising to get a person on your team, what it costs to train the person, and how long you need to train them. Youll learn what you are spending when your employees are not producing at the expected levelbecause they werent trained fully. Youll read about IT costs like setting up email addresses and getting them on your software. And after you look up all the costs you can track, think about what you cant track. How much time and money did you spend getting them shirts and swag?

After we lost the three guys in such quick succession, I added up the expenses and was blown away by what it cost to hire themcash right out the window.

Unsure what to do, I talked to my coach, and he gave me the kick in the ass I needed to work on the businesss core values. My partner Jimmy and I had some intense conversations to drill down into what we wanted our core values to be. Jimmy believes in a lot of things I dont and vice versa, but that didnt matter. We needed to work through these differences to agree on our core values.

Once we did that, our company strengthened. It didnt happen overnight, but it did happen. Get clear on your core values, and you will be amazed at what you are actually attracting to your business. It changes every aspect of your business, even the bottom line!

You never know when the perfect person for your organization is going to come along. So always be open to hiring people. With your core values in place, your process to bring them on-board will be that much easier and more economical. You will always be in the best position to grow your company and optimize every hiring opportunity.

__

Have you read the original anthology that was the catalyst for The Good Men Project? Buy here: The Good Men Project: Real Stories from the Front Lines of Modern Manhood

All Premium Members get to view The Good Men Project with NO ADS.

Need more info? A complete list of benefits is here.

__

Original article appeared at Tomas Keenan. Reprinted with permission.

Image by Gerd Altmann from Pixabay

Originally posted here:
Breaking the Small Business Owners Curse: Hiring for Longevity - The Good Men Project

Read More...

How to live longer: Avoid this eating habit to increase life expectancy – Express

January 18th, 2020 8:41 pm

Leading a long and fulfilling life largely hinges on your ability to avoid chronic complications that shorten your lifespan.

One of the most important proactive measures you can take is to maintain a healthy weight because obesity can lead to life-threatening conditions such as coronary heart disease.

In fact, coronary heart disease is one of the biggest killers in the UK and worldwide so it is important to maintain a healthy weight to ward off the threat of developing this deadly disease.

Intermittent fasting, an eating pattern that involves cycling between periods of eating and fasting, has been shown to attack this harmful belly fat, however.

A large review of studies found that following an intermittent fasting style of eating helped reduce visceral fat by four to seven percent over a period of six to 24 weeks.

Intermittent fasting has also been shown to provide benefits to heart health.

The dietary approach has been shown to offer protection against mechanisms that lead to heart disease.

Studies have found that intermittent fasting can improve blood pressure, total and LDL cholesterol, blood triglycerides, inflammatory markers and blood sugar levels - risk factors associated with the deadly condition.

In addition to a healthy dietary approach, numerous studies show that regular exercise can extend your lifespan.

In fact, a recent study presented at the American College of Cardiology's 68th Annual Scientific Session, reveals the health benefits of exercising over the age of 70.

The study found that being physically fit provides a more complete picture of an older persons health than the typical cardiovascular risk factors such as high blood pressure, high cholesterol, diabetes and smoking.

Seamus P. Whelton, MD, MPH, assistant professor of medicine at Johns Hopkins School of Medicine and the study's lead author, said: "We found fitness is an extremely strong risk predictor of survival in the older age group - that is, regardless of whether you are otherwise healthy or have cardiovascular risk factors, being more fit means you're more likely to live longer than someone who is less fit.

The findings, based on an analysis of more than 6,500 people medical records, found that higher fitness was associated with significantly increased rates of survival.

The most fit individuals were more than twice as likely to be alive 10 years later compared with the least fit individuals.

In light of the findings, Whelton called on doctors to incorporate it into their health assessments of older age patients: Assessing fitness is a low-cost, low-risk and low-technology tool that is underutilised in clinical practice for risk stratification.

Go here to read the rest:
How to live longer: Avoid this eating habit to increase life expectancy - Express

Read More...

Why Taylor Swifts Lover Has Greater Chart Longevity Than Reputation – Forbes

January 18th, 2020 8:41 pm

NEW YORK, NEW YORK - DECEMBER 13: Taylor Swift performs during the 2019 Z100 Jingle Ball at Madison ... [+] Square Garden on December 13, 2019 in New York City. (Photo by Taylor Hill/FilmMagic)

Taylor Swifts Lover just reached its 20th week on the Billboard 200, and with it, a not-so-rosy milestone: Its tied for its lowest chart position to date, landing at No. 13 just as it did in its 16th week. Jokes aside, thats another stellar hold in a history of stellar holds for Lover, which thus far has spent all of its 20 weeks inside the Top 15 and 17 weeks inside the Top 10. Swifts latest album has already occupied the Top 10 for five more weeks than Reputation did throughout its entire run, supporting my previous prediction that, despite a smaller debut, Lover will have a longer shelf life than Reputation.

There are a few explanations for Lovers greater chart longevity, both qualitative and quantitative. But first, lets look at the circumstances of Reputations massive debut of 1.238 million album-equivalent units, of which 1.216 million were pure sales. Reputation was preceded by the explosive lead single Look What You Made Me Do, a chilly, opulent revenge fantasy put to music that inadvertently addressed her long-standing feud with Kanye and Kim Kardashian West. Following a full-scale social media blackout, Look What You Made Me Do shot to No. 1 on the Billboard Hot 100 and broke first-day streaming records, generating loads of hype for Reputation. Swift withheld the album from streaming services upon release in November 2017, forcing fans to buy a physical copy or download it on iTunes if they wanted to hear the feature-length version of her airing grievances and torching her professional nemeses. This excitement and scarcity allowed Reputation to perform like a blockbuster superhero movie sequel, topping the Billboard 200 in its first three weeks, during which it also enjoyed a boost from holiday shoppers.

Reputation posted excellent holds throughout its first 11 weeks, lingering in the Top 10 and returning to No. 1 in its fifth and seventh weeks. But once it fell out of the Top 10 in its 12th week (No. 13), it wilted quickly, tumbling to No. 23 in its 15th week and bouncing between the high teens and low 20s on the Billboard 200 over the next several frames. Despite its early meteoric success, Reputation polarized some listeners with its chilly electro-pop sound and bad girl persona. Reputation spawned one more Top 10 single in ... Ready for It? (No. 4) and was certified 3x platinum by the RIAA, but it ultimately proved a relative underperformer compared to the 9x platinum 1989 and 7x platinum Red. Swifts venomous new attitude and fixation on celebrity feuds were intriguing and salacious, but they were also exhausting. And while the actual songs on Reputation have aged much better than I would have initially predicted, its accompanying narrative and heavy media exposure burned out some listeners, making it her most commercially front-loaded album to date.

The circumstances of Lovers release were almost entirely different. It was the first Swift album to be made available physically and on streaming services simultaneously, and it was her first album since 2010s Speak Now to not spawn a No. 1 lead single. (And it has yet to do so: ME! and You Need to Calm Down both debuted and peaked at No. 2 behind Lil Nas Xs Old Town Road.) By releasing Lover concurrently on streaming services and physically, Swift gave listeners the chance to tune out of the album after a few songs or cherry-pick their favorites for future listening, rather than buying the full album once and then determining which songs they liked most. Since Swift historically does not perform as well as some of her pop star peers (Drake, Ariana Grande, Billie Eilish) on streaming services, this release strategy likely resulted in fewer album-equivalent units than if she had only released Lover physically. As a result, Lover ended Swifts four-album streak of million-plus debuts, bowing with 867,000 units, of which 679,000 were pure salesa mammoth total for any pop star, but still a notable decline for Swift.

Yet what Lover sacrificed in first-week sales, it has recouped through repeat streams over the past several months. The album held strong in the Top 10 for its first 15 weeks, only dipping in week 16 thanks to an onslaught of Christmas albums flooding the Billboard 200. It has been jostled around over the past few weeks but never dipped below No. 13. So far, Lover has accumulated approximately 1.705 billion Spotify streams, versus Reputations 2.267 billion, despite coming out nearly two years earlier. And while Lovers lead single missed the top spot on the Hot 100, its second and third singles performed comparatively better than those on Reputation: You Need to Calm Down and Lover peaked at Nos. 2 and 10, respectively, while ... Ready for It? and End Game reached Nos. 4 and 18.

At a certain point, these granular statistics stop being useful for painting a portrait of an albums success. Still, I expect Lover to continue performing well on streaming services and eventually close the gap between it and Reputation. It helps that Lover has three more songs than Reputation to rack up more streaming-equivalent albums. More importantly, it helps that Lover contains more genuinely catchy pop songs that display greater emotional range for Swift. While Lover has not yielded another breakout or viral hit recently, songs like Cruel Summer, The Man and Cornelia Street have great commercial potential if Swift does choose to release one as a single. After her new documentary, Miss Americana, hits Netflix on Jan. 31, the album will likely see an uptick in sales and streams, particularly the films namesake track, Miss Americana & the Heartbreak Prince.

Simply put,Loveris more musically and narratively diverse thanReputation, which endears it to repeated listens over a longer period of time. According to the RIAA, Lover still has a long way to go to match the sales of Reputation, as it has thus far only been certified platinum. (Notably, it was the only album of 2019 to sell 1 million pure copies.) But theres plenty of time for that to change, and we shouldnt expect Lover to depart the Top 20 anytime soon.

Like what you see? Follow me onTwitterfor more.

See the rest here:
Why Taylor Swifts Lover Has Greater Chart Longevity Than Reputation - Forbes

Read More...

Advances in Cell and Gene Therapy and Opportunities in China – BSA bureau

January 17th, 2020 10:49 am

GenScript Biotech Global Forum Highlights Advances in Cell and Gene Therapy and Opportunities in China

GenScript Biotech Corp., a leading global biotechnology group and a pioneer in the field of gene synthesis, held its inaugural "Global Forum on Cell & Gene Therapy and the Booming China Market," during the JP Morgan Healthcare Conference week, attracting hundreds of industry leaders, investors and others to address the challenges and opportunities in this innovative field.

"As an industry, we are on the brink of achieving some extraordinary breakthroughs in cell and gene therapy for cancer and other diseases," said GenScript Biotech CEOFrank Zhang, PhD. "Four gene and cell therapies have recently been approved by the FDA, bringing new hope to patients, and this is only the beginning. Our vision is to make cancer a chronic or curable disease rather than a deadly one, and to transform the treatment of cancer, autoimmune and other diseases by leveraging the advantages of cell and gene therapy."

While significant advances are being made, the Forum also tackled some of the more pressing challenges, such as mitigating treatment side effects, improving treatment efficacy in solid tumors and scaling up manufacturing. Panelists from Kite Pharma, GE Healthcare Life Sciences, Ziopharm Oncology, Oxford Biomedica, Genethon, CARsgen Therapeutics, J&J Innovation Asia Pacific, the American Society of Gene & Cell Therapy, Loncar Investment, Lilly Asia Ventures, and many others participated in the event.

In the U.S. alone, the U.S. Food and Drug Administration is expected to approve 40-60 cell and gene therapies by 2030. During a panel discussion focused on regulatory issues, experts considered what regulators will need to do to keep up with the rapid pace of innovation, the new hospital-based regulatory pathway inChina, how to ensure quality through the manufacturing process, and the challenges and opportunities that come with regulatory harmonization among different countries.

Chinacontinues to attract significant attention from industry and investors and is poised to grow even more. During his welcoming remarks, Zhang notedChina'semergence as a global economic leader, with a projected$1.1 trillionspend on healthcare this year, as well as the growing disease burden inChina. By 2030, an estimated 4.3 million Chinese will be diagnosed with one of the 14 major cancers, according to research from IMS Health. Panelists addressed issues such as the amount of capital required to achieve scale inChina, and advantages of the market inChina.

"The drug development business is changing rapidly andChinais at the fore in a number of ways," Zhang said. "Biotech and pharma companies do not need or desire to have the infrastructure to scale their drugs through commercialization. With lower costs,Chinais a natural place for companies to contract out costly development and manufacturing to organizations that have the expertise and experience to collaborate with them through the entire discovery to development lifecycle."

For its part, GenScript has put significant resources into its Contract Development and Manufacturing Organization (CDMO) business to meet the increasing demand. In 2018, the company officially launched its biologics CDMO segment, and last year opened a new GMP compliant biologics research center. GenScript is also leading the way in cell therapy through its antibody discovery service and plasmid and virus production capabilities.

Read more:
Advances in Cell and Gene Therapy and Opportunities in China - BSA bureau

Read More...

UK accounts for 12% of cell and gene therapy trials – report – – pharmaphorum

January 17th, 2020 10:49 am

The UK accounts for over 12% of global cell and gene therapy clinical trials, according to new data published by a government-backed agency.

The Cell and Gene Therapy Catapult (CGT Catapult) today released its 2019 UK Advanced Therapy Medicinal Products (ATMPs) clinical trials database showing that the 127 ongoing trials represent a 45% increase compared with 2018.

According to the CGT Catapult this means the NHS and UK life sciences R&D centres are working well to allow innovative therapies to progress through to the clinic.

Publication of the figures comes the day after the government announced a deal with Novartis to bring cholesterol drug inclisiran to patients in England, and the announcement of an updated life sciences industrial strategy aimed at stimulating private investment in the sector.

Cell and gene therapies require specialist systems and infrastructure and according to the CGT Catapult the UK is being recognised internationally with the majority of commercially sponsored trials being backed by international organisations.

The database shows that 77% of UK cell and gene therapy trials are now sponsored by commercial organisations compared to only 25% in 2013.

The main therapy area for cell and gene therapies clinical trials remains oncology (39%) followed by ophthalmology (13%) and haematology (12%).

While the majority of trials are in the recruitment phase, the number of trials recruiting is considerably larger than previous years.

In 2019, there were 90 cell therapy trials recruiting patients, compared with around 55 in 2018, and the data suggest that these trials are quickly moving through planning and regulatory approvals to recruitment stage.

Around 65% of trials involve autologous cells, sourced from individual patients, with the remainder being off the shelf allogeneic products.

Established as an independent centre of excellence the CGT Catapult is funded by the government through Innovate UK.

It aims to encourage inward investment from big pharma and other international companies by bridging the gap between scientific research and full-scale marketing.

Keith Thompson, CEO of the Cell and CGT said: The total number of cell and gene therapy clinical trials in the UK has been increasing consistently by an average of 25% year on year since 2013. This has been enabled by the development of the UKs fantastic ecosystem to support the development and clinical adoption of cell and gene therapies.

The full report is available here.

Continue reading here:
UK accounts for 12% of cell and gene therapy trials - report - - pharmaphorum

Read More...

Why gene therapy is set to transform medicine – Digital Journal

January 17th, 2020 10:49 am

Gene therapies are in the in-demand medicine, due to their potential to treat life-threatening diseases, including illnesses classified as rare genetic diseases. Examples include treating sickle cell anemia and anti-tumor immunotherapy. As well as being demand, the market is also lucrative, expected to grow to $11.96 billion by 2025. The growth with gene therapies is represented by the range of gene therapy products in the clinical pipeline, where Frost and Sullivan estimate some 400 cell and gene therapy products in development. The last year alone has seen a 27 percent increase in the number of clinical trials involving gene therapy products. This is also reflected with the number of emergent start-up companies entering the gene therapy space. Most start-up companies elect to outsource the downstream manufacturing stages, due to the relatively low costs involved, as off-set against the costs involved with constructing specialist facilities. Big Pharma is also investing in the field. For example, Pfizer has injected $500 million into one of its plants in North Carolina and Fujifilm Diosynth has made a similarly large investment to boost production capability. READ MORE: Revolutionizing the CRISPR methodThe growth has been fuelled by support from governments and regulatory agency. Here the U.S. 21st Century Cures Act as been a key driver, supported by the U.S. Food and Drug Administration (FDA). There are, however, some limitations to be overcome. One limitation with progressing gene therapy products is with costs and pricing structures, which is resulting in many therapies being unstainable. This is also limiting the transition to scale, given the complexities tied to growing, sourcing and transporting cells. Costs are high partly as a result of the development and partly because many gene therapies offer curative solutions, making them an in-demand and expensive medicine. A solution to the costs factors is, according to Vered Caplan (Orgensis Inc) the development of point-of-care automation, including the application of closed systems for processing cell therapies. These systems require the use of fewer personnel and permit real-time quality control testing to take place. A second limitation is with the availability of rare materials of sufficient quality, such as plasmid DNA and tranfection agents), which need to be manufactured under the same standards applied to mainstream pharmaceuticals (that is, Good Manufacturing Practices. With new technology emerging to improve product yield and to drive down costs, coupled with increased investments, the expansion of gene therapy products looks set to be one of the big drivers within healthcare over the next five years.

Follow this link:
Why gene therapy is set to transform medicine - Digital Journal

Read More...

Precision BioSciences hits two key FDA milestones in advancing gene therapy for cancer – WRAL Tech Wire

January 17th, 2020 10:49 am

Precision BioSciences, a Durham-based genome editing company, has reached two regulatory milestones for its potential therapy against multiple myeloma, a chronic cancer of white blood cells.

The U.S Food and Drug Administration (FDA) has accepted the companys Investigational New Drug (IND) application and also granted the therapy Orphan Drug Designation, a status that gives companies tax reductions and other incentives to develop treatments for rare diseases.

The therapy, designated as PBCAR269A, is Precisions third allogeneic chimeric antigen receptor (CAR) T cell therapy candidate.

FDA acceptance of the IND for PBCAR269A further underscores the ongoing progress in our allogeneic CAR T pipeline, said Matt Kane, co-founder and chief executive officer of Precision BioSciences. We have now moved three CAR T programs from preclinical to clinical stage development since April 2019, and we look forward to continuing to advance our allogeneic CAR T portfolio to bring these novel therapeutic candidates to patients.

Matthew Kane

The company plans to begin a Phase 1 clinical trial of the therapy this spring at multiple sites using material produced at its own manufacturing facility in Durham. About 48 patients are expected to be enrolled.

For more information about the trial, visitwww.clinicaltrials.gov, and enter study identifier number NCT04171843.

In preclinical disease models, PBCAR269A has demonstrated no evidence of graft-versus-host disease at doses that resulted in potent anti-tumor activity, said Chris Heery, M.D., chief medical officer of Precision BioSciences. There remains significant unmet need in the treatment of relapsed/refractory multiple myeloma, and we are excited to begin clinical trials with an off-the-shelf CAR T therapy candidate in this setting.

The IND for PBCAR269A builds on the initial clinical data Precision presented in late 2019 for its lead program, a CAR T therapy for treating non Hodgkins lymphoma and B-cellacute lymphoblastic leukemia, and the FDAs acceptance of an IND for another CAR T therapy for treating non-Hodgkins lymphoma, chronic lymphocytic leukemia and small lymphocytic lymphoma.

Precision BioSciences harnesses T cells, a type of white blood cell that is vital to the adaptive immune systems ability to identify specific antigens and destroy pathogens. Through the companys CAR T technology, the T cells can be directed to kill cancer cells.

Precision produces the CAR T therapies by selecting T cells derived from healthy donors as starting material. Then, using its proprietary ARCUS genome-editing technology, the company modifies the donor T cells.

Scientists insert the CAR gene at the T cell receptor locus, enabling the T cell to target a specific marker on a cancer cell, while knocking out the T cell receptor to prevent the patients immune system from recognizing and attacking the T cells.

The company optimizes its CAR T therapy candidates for immune cell expansion in the body by maintaining a high proportion of certain types of CAR T cells throughout the manufacturing process and in the final product.

The process creates a consistent product that can be reliably and rapidly manufactured and is designed to prevent graft-versus-host disease, normally a major challenge when inserting foreign or altered cells or tissues into the body.

The company has posted a four-minutevideoon its website to explain CAR T therapy, using Samurai warriors as an analogy.

Last July Precision opened its Manufacturing Center for Advanced Therapeutics (MCAT), the first in-house current Good Manufacturing Process (cGMP)-compliant manufacturing facility in the United States dedicated to genome-edited, off-the-shelf chimeric antigen receptor CAR T cell therapy products.

Precision Bio facility

Given the potential output of our platform, weve known from the beginning that it was critical for us to address the need for scalable manufacturing of cell-therapy products in order to be able to effectively deliver them to patients, Kane said when the facility opened. In addition to our clinical work, it also has the potential to be a commercial launch facility with the capacity to generate up to 10,000 doses of CAR T cell therapies and 4,000 doses of gene therapies per year.

The facility can produce three different drug substances: allogeneic CAR T cells, messenger RNA and adeno-associated viral vectors. It was designed to meet regulatory requirements in the United States, Europe and Japan.

In addition to health care, Precisions ARCUS genome-editing platform has applications in food and agriculture.

In 2018 the company created a new name and brand identity, Elo Life Systems, for its food and agriculture business, previously known as Precision PlantSciences, based in Research Triangle Park.

Elo is using the ARCUS platform and other new technologies for applications in crop improvement, animal genetics, industrial biotechnology and sustainable agriculture.

Since it was spun out of Duke University in 2006, Precision raised about $300 million in venture capital, government grants and collaboration agreements. The company went public in March 2019, grossing $145.4 million in an initial public offering of stock.

The companys shares are listed on the Nasdaq Global Select Market under the ticker symbol DTIL, shorthand for the companys marketing tagline, Dedicated to improving life.

(C) N.C. Biotech Center

Original post:
Precision BioSciences hits two key FDA milestones in advancing gene therapy for cancer - WRAL Tech Wire

Read More...

ASC Therapeutics and Vigene Announce Long-Term Strategic Partnership for Gene Therapy Development and Manufacturing – Yahoo Finance

January 17th, 2020 10:49 am

ASC Therapeutics ("ASC"), a privately-held gene therapy company focused on developing transformative gene-based medicines for serious diseases, announced today that it has entered into a long-term strategic manufacturing partnership with Vigene Biosciences ("Vigene"), a Maryland-based Contract Develop and Manufacturing Organization (CDMO). Vigene will provide ASC with access to GMP manufacturing including viral vectors and plasmid DNA for its hemophilia A gene therapy clinical program, as well as a manufacturing platform for future gene therapy programs.

"The genetic platform technology developed by ASC is going to change the way serious diseases are treated in the future. We have seen remarkable potency data in our Hemophilia A IND-enabling gene therapy studies," said Dr. Ruhong Jiang, ASC Founder & CEO.

Dr. Jiang continued, "We are proud to welcome Vigene, a global leader in gene therapy process development and GMP manufacturing with a proven track record and expertise in the field of viral vector manufacturing, to become an integral part of ASC long-term plan. Our partnership provides ASC access to Vigenes world-class team with expertise for both plasmid DNA and viral vector manufacturing as well as high-caliber QC and QA teams."

"Vigene is excited to become a long-term CMC partner for ASC with multiple newly built, state-of-the-art GMP suites and high-titer virus producer cell lines, we are well positioned to support ASC for both early-stage and commercial virus production. This partnership will ensure that all ASC clinical deliverables are achieved in a timely fashion," said Dr. Zairen Sun, Vigenes President and CEO. "We have a world-class manufacturing team, and this agreement is a testimony for our recognition by top-tier biopharmaceutical companies."

About ASC Therapeutics

ASC Therapeutics is a biopharmaceutical company dedicated to advancing an integrated and sustainable pipeline focused on gene therapies that correct the root cause of complex and intractable diseases. We are leveraging our AAV-based gene therapy, CRISPR-Cas9 and proprietary gene editing platforms consolidated over 10 years to develop transformative gene-based medicines. ASC is accelerating through clinical trials several lead gene therapies for inherited blood disorders. Our team of industry veterans in discovery, pre-clinical, clinical and CMC gene therapy development and world-class academic and biopharmaceutical partnerships are potentiating our gene therapy capabilities. To learn more about ASC Therapeutics, please visit http://www.asctherapeutics.com.

About Vigene Biosciences

Vigene Biosciences is an award-winning and private equity backed leader in gene delivery development and manufacturing. Vigene has 16 years of cGMP viral vector production experience. Vigenes mission is to make gene therapy affordable. Vigene offers IND-enabling and IND-supporting materials as well as FDA- and EMA-compliant commercial products for plasmid, AAV, lentivirus, and adenovirus with proven technologies and track records. The GMP facility features 10 GMP suites including 5 brand-new cGMP suites with 200L-500L single-use stir tank bioreactors for suspension cells as well as iCellis 500 for adherent cells. In 2018 and 2019 Vigene was recognized by INC500. In 2018, Vigene was chosen as the ACG Emerging Company of the Year Award. To learn more about Vigene Biosciences, please visit http://www.vigenebio.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005788/en/

Contacts

ASC Contact Information: Oscar Segurado, MD, PhDChief Medical OfficerASC TherapeuticsMilpitas, CA650.490.5199oscar.segurado@asctherapeutics.com

Vigene Contact Information: Jeffrey Hung, Ph.D.Chief Commercial OfficerVigene BiosciencesRockville, MD301.251.6638jhung@vigenebio.com

Link:
ASC Therapeutics and Vigene Announce Long-Term Strategic Partnership for Gene Therapy Development and Manufacturing - Yahoo Finance

Read More...

One-year Results in 2 Given Gene Therapy at Low Dose Showing… – Parkinson’s News Today

January 17th, 2020 10:49 am

Two Parkinsonspatients treated with AXO-Lenti-PD, an investigative gene therapy, in an ongoing clinical trial continue to show improvement 12 months later, Axovant, the therapys developer, said in a release.

These findings at one year after treatment are important because this timepoint allows for a better assessment of therapy durability, and a more assured differentiation between placebo effects and therapeutic response, the company added.

AXO-Lenti-PD has shown encouraging results in these two people given a first low dose in the SUNRISE-PD (NCT03720418) Phase 1/2 clinical trial, which is now enrolling up to 30 patients at sites in France and England.

The treatment works by delivering three genes involved in dopamine production directly to the brain via a surgical procedure.

Dopamine is a neurotransmitter a molecule involved in transmitting information between neurons that is critical to coordinating movement. Dopamine-producing (dopaminergic) neurons are lost in Parkinsons, and the resulting drop in dopamine levels is the cause of many disease symptoms.

By infecting brain cells with the genetic instructions to increase dopamine production, AXO-Lenti-PD aims to turn other cells into dopaminergic neurons.

Current dopamine replacement therapies require continual oral doses of dopamine, whose effectiveness fades over time. The period between when one doses effectiveness wanes and the taking of a next dose can result in off periods, wherein patients report a return of symptoms such as poor motor control, stiffness, fatigue and mood changes.

Helping the brain to again produce adequate levels of dopamine would, in theory, eliminate the need for periodic oral doses, which could significantly limit off periods.

Previous studies in primate models of Parkinsons found AXO-Lenti-PD to be safe and effective, and SUNRISE-PD results at three months post-treatment found that a one-time delivery of the therapy significantly improved patient scores on theUnified Parkinsons Disease Rating Scale (UPDRS), a standard assessment of motor and non-motor symptoms associated with Parkinsons.

The trial consists of two parts. Part A is an open-label, dose-escalation phase in which patients receive one of potentially three escalating doses of the gene therapy. In part B, a new group of patients will be randomized to either the ideal part A dose or to a sham procedure as an untreated control group. SUNRISE-PDs goal is to test the safety, tolerability, and effectiveness of the potentialtreatment.

Both patients here, the first two enrolled, received the lowest dose (4.2106transducing units) of AXO-Lenti-PD.

One-year results showpositive changes of 24 points and 20 points (respectively for the two patients) on the UPDRS Part III Off score, representing a 37% improvement in off-period motor symptoms, Axovant reported. Improvement at six months was 29%, as measured on the same scale.

These patients also showed an average 13-point positive change from baseline (study start) representing a 44% improvement on the UPDRS Part II Off score, which assesses daily life activities. On the PDQ-39 score index, another quality-of-life measure in Parkinsons disease, these two showed an average 15-point positive change, or a 30% improvement from baseline to 12 months.

Both patients tolerated AXO-Lenti-PD well, and neither reported any serious side effects. One maintained a diary of on/off periods, which is useful in evaluating changes that might be due to therapy across time.

People being enrolled in SUNRISE-PD have had Parkinsons for at least five years, have motor fluctuations and dyskinesia (jerky, involuntary movements), and are between the ages of 48 and 70. More information can be found here.

The company expects to soon release six-month results on the first two patients given a second and higher dose of AXO-Lenti-PD. This dose is three times higher than that given the first cohort.

If dose-escalation results allow, Axovant expects to begin the randomized and placebo-controlled part B of the SUNRISE-PD as a Phase 2 study by the close of 2020.

Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.

Total Posts: 208

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

Here is the original post:
One-year Results in 2 Given Gene Therapy at Low Dose Showing... - Parkinson's News Today

Read More...

Global Gene Therapy Market 2019-2030: Promising Therapeutics Areas – Yahoo Finance

January 17th, 2020 10:49 am

Dublin, Jan. 13, 2020 (GLOBE NEWSWIRE) -- The "Gene Therapy Market (3rd Edition), 2019-2030" report has been added to ResearchAndMarkets.com's offering.

The Gene Therapy Market, 2019-2030 report features an extensive study of the current market landscape of gene therapies, primarily focusing on gene augmentation-based therapies, oncolytic viral therapies, and genome editing therapies. The study also features an elaborate discussion on the future potential of this evolving market. Amongst other elements, the report features:

Key Topics Covered:

Some of the Companies Mentioned include:

For more information about this report visit https://www.researchandmarkets.com/r/nuaak0

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Read more:
Global Gene Therapy Market 2019-2030: Promising Therapeutics Areas - Yahoo Finance

Read More...

What has the most impact on longevity? – Harvard Health

January 17th, 2020 10:49 am

Published: February, 2020

Q. My family tends to be long-lived. I hear longevity is due to our DNA, and I also hear it's due to lifestyle. Which is it, and how do they make us live longer?

A. Both DNA and lifestyle can affect longevity, and they both do so in the same way: by altering our body chemistry. DNA controls the production of each of the natural chemicals in our body. It controls both the shape (and, hence, the effectiveness) of each chemical, and also controls how much of that chemical is made. So, it's not surprising that DNA could affect longevity. In the past 20 years, astonishing progress has been made in understanding the body chemistry that controls the aging process. And that knowledge has allowed scientists to extend the life of various animals through simple genetic manipulations.

Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.

Originally posted here:
What has the most impact on longevity? - Harvard Health

Read More...

Frazier closes 12th fund in 30 years, with $617M to bet on cell/gene therapy, Big Pharma spinoffs and more – Endpoints News

January 17th, 2020 10:49 am

The team at Frazier Healthcare did a number of deals that exemplified its wide-ranging strategy in 2019: Tachi Yamada worked with gene therapy pioneer Jim Wilson to launch Passage Bio; Mike Gallatin sold Mavupharma and its STING-targeted small molecule to AbbVie; and Bhaskar Chaudhuri flipped Arcutis to an IPO just months after introducing it to the world via a crossover round close to $100 million. Theyre now kicking off 2020 with a new, bigger fund that will give them firepower to do more.

At $617 million, Fund X is fairly dramatically bigger than their last fund, said managing partner Patrick Heron.

Were increasingly going after new therapeutic modalities like gene therapy, cell therapy, neoantigens and because those need significant manufacturing and CMC investment or investing more dollars per company, he told Endpoints News.

He sees Frazier pouring around $40 million into each company supporting them through every stage, whether its helped with the launch or joined through a later syndicate though that could vary if, say, they sell a company right after Series A. By that estimate, the new fund could touch anywhere from 15 to 25 biotechs.

About a third of the portfolio is reserved for homegrown startups, another 15% to 25% for public securities, and the rest is in-between.

Heron is one of three leading the fund; hes joined by managing partner James Topper and Dan Estes, whos just been promoted to general partner. Also involved will be Jamie Brush, newly made partner after spearheading investments in public securities for the past three years.

Frazier is happy to both create and syndicate with its venture brethren, Heron added, citing OrbiMed as a friend.

The congregation has grown exponentially since Frazier first put its feet down three decades ago.

When I started at Frazier, there were probably 10 to 15 life sciences focused VC funds, said Heron, whos just celebrated his 20th year at the firm, and now theres probably 100.

It gives Frazier a lengthy track record to boast which can be particularly helpful when they pitch bigger players on biotech spinoffs such as Phathom Pharmaceuticals, now developing one of Takedas GI drugs.

Pharma companies have become more receptive to that when they see substantial value accrual to them, Heron said. And its public now: Takeda owns probably about $200 million worth of stock in Phathom, and so they are basically deriving a lot of economic value from the partnership, and what theyre also focused on is the quality of teams we can put around their asset such that the program will reach the clinic and benefit patients.

Two former Celgene execs from the global inflammation and immunology franchise have been recruited to the C-suite at Phathom, including CEO Terrie Curran and CCO Martin Gilligan.

Despite the lack of big check M&A at the beginning of the year and an election looming in November, Heron remains optimistic as their deal flow has been in line with the expectation of 2 to 3 sales per year. And the same goes for IPO.

I think you will see a lot of companies sort of backing up the truck and loading up with as much capital as they can, with probably less robust activity in the second half of the year, he said.

Continue reading here:
Frazier closes 12th fund in 30 years, with $617M to bet on cell/gene therapy, Big Pharma spinoffs and more - Endpoints News

Read More...

4 health and wellness events worth seeking out in Austin this weekend – Hoodline

January 17th, 2020 10:48 am

Want to up your game when it comes to health and wellness?

From free barre class to seminar on human touch, there's plenty to do when it comes to holistic activities to enrich your weekend. Read on for a rundown.

Hoodline offers data-driven analysis of local happenings and trends across cities. Links included in this article may earn Hoodline a commission on clicks and transactions.

From the event description:

When: Saturday, Jan. 18, 9:30-10 a.m.Where: Adelante Austin, 1206 W. 38th St.Admission: Free

Click here for more details, and to get your tickets

From the event description:

When: Saturday, Jan. 18, 10 a.m.-1 p.m.Where: River City Wellness, 8708 S. Congress Ave., Suite 570Admission: $5 (Early Bird)

Click here for more details, and to get your tickets

From the event description:

When: Saturday, Jan. 18, 1-2:30 p.m.Where: Cancer Rehab and Integrative Medicine, 4130 Spicewood Springs RoadAdmission: Free

Click here for more details, and to get your tickets

From the event description:

When: Saturday, Jan. 18, 7-9 p.m.Where: Cenote - Windsor Park, 6214 Cameron RoadAdmission: Free

Click here for more details, and to get your tickets

This story was created automatically using local event data, then reviewed by an editor. Click here for more about what we're doing. Got thoughts? Go here to share your feedback.

Follow this link:
4 health and wellness events worth seeking out in Austin this weekend - Hoodline

Read More...

Robby Andrews Lyme Disease Recovery | Running With Lyme Disease – Runner’s World

January 17th, 2020 10:48 am

In early June of 2018 elite middle-distance runner Robby Andrews was on fire. Was, unquestionably, at the top of his running game. The then-27-year-old had just run one of his fastest races ever: 3:36 in the 1500 meters at the Oslo Diamond League Meet in Norway, beating out 18-year-old phenom Jakob Ingebrigtsen. Which is why, for Andrewswinner of the 800-meter national outdoor title in high school, holder of a national indoor record in the 800 meters as well as the 1000 meterswhat happened two weeks later was such a shock.

June 21. The USATF Championships in Des Moines, Iowa. Andrews felt confident going into the 1500 meters, but mid-race he completely ran out of steam. He placed a disappointing fifth in his heat, not even qualifying for the finals. I dont know what happened, a confused Andrews told reporters after the race.

Kevin Morris

A few days later he came down with flu-like symptoms. For the next month he battled nasty upper respiratory and sinus infections and 102-degree fevers. Training just sucked, says the Olympian. My paces were nearly 40 seconds slower than theyd been just a few weeks before. Andrews went to his doctor, who ran tests for everything from Lupus to Lyme, but they all came back negative. I was told, There is literally nothing wrong with you, recalls Andrews. But there had to be, he knew. This could not possibly be all in his head.

Still, he had a contract with Adidas to fulfill, so Andrews traveled to Europe, where he clocked disappointing times: 3:44 in the 1500 meters at the Lignano Meeting International in Italy; 1:52 in the 800 meters in Flanders Cup Kortrijk in Belgium. For the remainder of the summer, Andrews felt constantly wiped out. Normally he would be up at 7:30 to train; now, he couldnt pry himself out of bed until 10. The few days a week he forced himself to run, hed get so dizzy and breathless hed have to quit after 20 minutes. Every afternoon, he napped for up to four hours.

He kept thinking how closely his symptoms resembled those of people he knew whod had Lyme, including his older sister Kristin (also a runner who is a 2020 Olympic hopeful) and his former roommate, Donn Cabral (a 2012 and 2016 Olympian in the 3,000-meter steeplechase), so Andrews asked to have his Lyme test re-run in September. It came back positive. The doctor wanted to prescribe antibioticsthe standard treatment for Lymeimmediately, but Andrews was worried about the side effects. Instead, he decided to take the advice of a holistic doctor who had helped his sister during her bout with Lyme in 2016.

Once a week Andrews swallowed eight drops, an hour aparta concentration of herbs such as ashwagandha, rhodiola, turmeric, licorice root, and cordycep mushroomsthat the holistic doctor said would help strengthen his immune system. He soaked his feet in a proprietary blend of herbs that he was told would draw toxins out of his body. He spent more than $1,000 on treatment. He didnt care if anyone thought he was nuts. He just wanted to feel better.

And he did, for a few months. My energy went way up. I could run three miles without having to stop, says Andrews. Then, in February, it all fell apartan almost overnight, dramatic decline in his physical and emotional health. Fatigue weighed down his body. Headaches crackled through his brain. He was sweating so much at night that he had to change the sheets. And perhaps the worst? Really depressive thoughts. It was a dark couple of months, Andrews says. If it wasnt for my girlfriend and family, I would have gone days without talking to anyone or leaving the house. He raced at the U.S. Championships at the end of February on Staten Island, in the 1000 meters. I felt bad from the first step. Something was wrong. He clocked in at 2:26dead last.

Drew Reynolds

Patrick SmithGetty Images

Disillusioned with the holistic protocol, Andrews finally accepted a prescription for antibiotics in March. His doctor told him to take them until his symptoms were relieved for a full month. Andrewss concerns about side effects were valid; the antibiotic gave him severe fatigue and headaches, brain fog and GI issues.

Desperate to make the 2019 world championship team, he ran the 800 meters at the Adrian Martinez Classic in April, only to come in last, again. In June he set his sights on the Princeton Qualifier. I missed my college roommates wedding for it, that is how important this race was for me, he says. Midway through the 1500-meter race, he dropped out, wheezing and depleted.

Andrews felt like he was out of options. And although he didnt know it at the time, he had entered the Lyme Wars, a fiercely contested fight about why some Lyme patients develop chronic, relapsing symptoms even after treatmentand what to do about them.

A stealth pathogen. Thats what some researchers call the corkscrew-shaped bacteriaBorrelia burgdorferithat causes Lyme disease, now one of the fastest growing infectious diseases in America. More than 300,000 new cases are diagnosed every year, according to estimates from the Centers for Disease Control and Prevention (CDC).

Black-legged ticks pick up Borrelia from the birds and small mammals they feed on, then they pass the bacteria into our blood when they feed on us, usually from May to Septemberprime months for logging miles on wooded trails and grassy park paths.

Removing a tick quickly lowers your risk for infectionit takes an estimated 36 to 48 hours for the arthropod to transmit Borrelia. But once the bacteria enters your body, it is a master of evasion. The Borrelia can spread from the skin to other tissues, which can make it more challenging to treat. Your immune system takes days to a few weeks to recognize any infection, including Lyme. Thats why the standard Lyme testwhich checks for antibodies (not the bacteria itself)can more easily give a false negative test early on, like Andrewss did.

When your body finally detects Borrelias presence, it launches an immune response to fight it, which is what can bring on flu-like symptoms such as sluggishness, fatigue, muscle aches, and joint pain. Runnersespecially those who spend hours outside during the summer training for fall marathonscan attribute symptoms to overtraining.

The majority of Lyme cases are easy to treat and cure with a 10- to 28-day course of antibiotics, says Paul Auwaerter, M.D., the president of the Infectious Diseases Society of America (IDSA). Ying Zhang, MD, Ph.D., a leading expert on the Lyme bacteria and a professor of molecular microbiology and immunology at the Johns Hopkins Bloomberg School of Public Health, disagrees. Lyme can be a really terrible disease and a very complex one. Different patients have different responses, and the disease can manifest in different ways, says Zhang, who believes Lyme can indeed develop into a chronic form that resists the current antibiotic treatment.

Indeed, for around 20 percent of Lyme patients, a dose of antibiotics isnt the end of the story. Not by a long shot. They continue to suffer from a variety of symptoms that can last for months, even years: fatigue, headaches, muscle and joint pain, difficulty concentrating, and sleep disruptions. The frequently used medical term for these persistent problems is Post-Treatment Lyme Disease Syndrome (PTLDS). PTLDS means that we know that a patient has had Lyme, has gotten a course of antibiotics, and doesnt feel like theyve bounced back, says Auwaerter.

PTLDS is often referred to as chronic Lyme, a term Auwaerter disparages as a catchphrase for otherwise unexplained fatigue, pain, and neurologic symptoms in people who dont meet the diagnostic criteria for Lymeusually obtained by medical history, a positive blood test, and physical exam. But diagnosing Lyme can be tricky. In the first three weeks after infection, the test detects Lyme only 29 to 40 percent of the time and some 30 percent of all Lyme patients, like Andrews, dont get the telltale bullseye rash.

Drew Reynolds

Drew Reynolds

What really keeps the controversy alive is this: There isnt yet a sensitive and reliable test that can determine if ongoing symptoms after Lyme treatment are due to an ongoing active infection, says Brian Fallon, MD, director of the Lyme and Tick-Borne Diseases Research Center at Columbia University. Without one, some medical organizations, like the International Lyme and Associated Diseases Society (ILADS), believe chronic symptoms may be due to the persistence of the Lyme bacteria. They suggest that for some patients, the potential risks of treating with antibiotics for longer periods of time outweighs the consequences of an untreated persistent infection. Giving credence to this argument are several recent studies that found Lyme bacteria remained in animals even after they were treated with antibiotics. And in March, Zhang and his colleagues found that a slow-growing form of persister Lyme bacteria not only resisted standard single antibiotic treatment, but also caused more severe arthritis-like symptoms in mice. They found that a cocktail of three antibioticsdaptomycin, doxycycline, and ceftriaxonecompletely killed the bacteria, and they are now planning clinical trials to see if the result is the same in humans.

On the other hand, groups including the IDSA maintain that symptoms that linger after antibiotic therapy are not due to an ongoing active infection of the Lyme bacteria and therefore should not be treated with additional rounds of antibiotics because theyre unlikely to help. Six clinical trials have shown that long-term antibioticsbeyond the recommended 28 dayare not effective, says Auwaerter. Plus, long-term use of antibiotics can lead to serious side effects, such as blood clots and, even, in rare cases, death.

If chronic symptoms are not caused by an active infection, then what? It could be due to an autoimmune reaction, where a prior infection has triggered an immune reaction that is now acting independently, or it could be that the prior infection changed the brain activation patterns, Fallon says. Theres some evidence to support both of these processes.

While researchers debate, patients are left sick, with lots of questions, and no good answers. Its devastating for peoples lives and some are willing to try anything to get better, Fallon says. After his dismal race in Princeton, Andrews was one of them.

This June, after battling symptoms for nearly a year, Andrews visited Mark Sivieri, M.D., a board-certified family practice doctor in Maryland who is also board certified in integrative medicine (which pairs traditional medicine with complementary therapies). Andrewss cousin had been seeing him for her own ongoing Lyme symptoms. There was an instant connection: Sivieri had also been a professional runner; he and Andrews even shared a coach at one point. During the three-and-a-half-hour appointment, Sivieri studied Andrewss previous blood tests. He noticed that, in addition to Lyme, Andrews had tested positive for two other tick-borne infections (Andrews says the doctor who had ordered the test never mentioned them).

Ticks carry and transmit loads of other bacteria, parasites, and viruses beyond Borrelia burgdorferi. A single tick can make a person sick with several diseases at the same time, including Anaplasmosis (a bacterial infection that causes fever, aches, chills, and muscle aches), Babesiosis (a parasitic infection that attacks red blood cells), and Powassan virus (which can cause an infection in the brain and can even be deadly). And not all doctors check for these when they are focused on Lyme; those who do test for them may believe the antibiotics prescribed for Lyme will be enough to wipe out the co-infections. The estimates for co-infection rates with Lyme disease can widely range anywhere from about two to 40 percent. And not only are some, such as Powassan, more dangerous than Lyme, but simultaneous infection, some research suggests, may make Lyme harder to treat or recognize, and might affect how the immune system responds to Burgdorferi.

Sivieri put Andrews on a 60-day course of the two antibiotics hed previously been taking to kill the bacteria for Lyme; he also prescribed a medication to wipe out the co-infections. He said the night sweats and the shortness of breath, thats what the Babesia parasite does, it eats your red blood cells and prevents the oxygen from moving around your body. Thats obviously a big concern for runners. I couldnt breathe well when running, right from the start, says Andrews. And Im a trained athlete.

Sivieris tests showed that Andrews was also sensitive to gluten and dairy; he recommended avoiding them to help take pressure off his immune system. My stereotypical Italian grandma was aghast when I told her no more pasta and chicken parmesan, Andrews says. That was a big transition for me. But if thats whats was going to get me better, I didnt care at all.

Drew Reynolds

Sivieri then turned to natural remedies to help strengthen Andrewss immune system, putting him on adaptogenic herbssaid to help with all types of stresssuch as curcumin which can reduce the inflammatory response caused by Lyme.

Using alternative medicine to nuke hard-to-kill bugs might sound like folklore, but science is starting to back the theory: Zhang recently found that, in laboratory dish tests, 10 oilsincluding from garlic cloves, myrrh trees, thyme leaves, allspice berries, and cumin seedsshowed strong killing activity against the non-growing and slow-growing persister forms of the Lyme bacteria, even better than standard antibiotics. We need to do proper clinical trials, to see how to use them more effectively without being toxic but [in the future, I believe that] the more effective treatment is going to come from a combined approach of antibiotics with essential oils or natural products.

The combination of traditional and alternative medicine helped Andrews. The past year has been brutal, but he finally feels like his old self again. I wake up in the morning and I have energy all day, he says. Im not sweating at night, [there are] no headaches. The depressive thoughts are gone. Im training at full capacity. He plans to run the indoor season in 2020, still in hopes of achieving the Olympic qualifying time.

He stopped taking antibiotics in mid-August, now its complementary treatmentsincluding vitamin C for his adrenals and immune system and curcumin for inflammation. He still avoids gluten and dairy and is content to continue the regimen for the near future. The supplements could be pointless, but hes not going to chance it. It seriously feels like I have my life back, he says. This is me. Im back to me.

Continue reading here:
Robby Andrews Lyme Disease Recovery | Running With Lyme Disease - Runner's World

Read More...

Myths may worsen low back pain and promote ineffective treatments – Midwest Communication

January 17th, 2020 10:48 am

Thursday, January 16, 2020 4:38 p.m. EST

By Vishwadha Chander

(Reuters Health) - Common myths about low back pain could lead to more pain, ineffective care and unwarranted anxiety, researchers say.

Low back pain is the world's leading cause of disability, and it's often associated with costly care that can sometimes be harmful, Peter O'Sullivan and colleagues write in an editorial in the British Journal of Sports Medicine.

Myths about back pain are common and can be reinforced by the media and well-meaning clinicians, the authors note.

This misinformation "can lead people to fear back pain, respond to it in unhelpful ways and drive poor healthcare," O'Sullivan said in an email. "Myths often cause negative emotional responses such as fear, distress and loss of hope," he added, as well as behaviors like over-protecting the back and avoiding movement, activity and work.

O'Sullivan, a specialist physiotherapist with the School of Physiotherapy and Exercise Science at Curtin University in Perth, Australia, told Reuters Health that almost daily, he comes across patients who hold unhelpful beliefs.

In their editorial, O'Sullivan and his colleagues identify 10 common myths about low back pain, and counter each of them with back pain facts that are supported by evidence.

Among the myths are the idea that low back pain will become persistent and will worsen with age, that pain is always a sign of tissue damage and requires rest, and that scans and invasive procedures are always needed to diagnose and treat low back pain.

In fact, the authors write, the evidence says persistent back pain can be scary, but it's rarely dangerous or life-threatening and it's unlikely to leave you in a wheelchair.

Getting older is not a cause of back pain, they add, and evidence-based treatments can help at any age. Persistent low back pain is rarely related to tissue damage and scans rarely show the cause of back pain.

Low back pain is not caused by poor posture while sitting, standing and bending, and it's also not caused by weak core muscles. Injections, surgery and strong drugs usually aren't effective for persistent back pain in the long term. Finding low-risk ways to control pain is key.

Dr. Houman Danesh, director of Integrative Pain Management at the Icahn School of Medicine at Mount Sinai in New York City, said it's common in his experience, too, to find patients holding beliefs like those in the list of myths.

"I usually have to spend a portion of my office visit untangling them, the most common being patients who say they have a herniated disc from 20 years ago and have chronic back pain. That is a rare occurrence," Danesh, who was not involved in the editorial, told Reuters Health in an email.

"It is sad and frustrating when patients take on a false identity based on a myth and lose a large part of their quality of life."

Danesh disagreed, however, with some of the authors' advice. For instance, there are cases when strong medications, injections or surgery can be used to treat low back pain, so that "is not entirely a myth," he said.

"There are times these treatments are necessary, and a medical evaluation is needed to determine the best course of treatment."

O'Sullivan said research into understanding back pain has increased, but societal beliefs and clinical practice were slow to catch up.

"Clinicians and doctors must spend time to ask patients what they understand about their back pain - its cause, consequences and how best to care for it - and then provide practical ways to manage it," he said.

SOURCE: https://bit.ly/2FuhlfI British Journal of Sports Medicine, online December 31, 2019.

Read more from the original source:
Myths may worsen low back pain and promote ineffective treatments - Midwest Communication

Read More...

OVR Technology Is Creating Olfactory Virtual Reality for Health Care, Education and Training – Seven Days

January 17th, 2020 10:48 am

My first experience with olfactory virtual reality was truly trippy. Wearing a VR headset and holding a controller in each hand, I stood in a 3D room at OVR Technology in Burlington, gazing at a virtual table holding plates of tomato slices, garlic bulbs and basil leaves. As instructed by Jesse Stein, vice president of product and marketing, I used the controllers to pick up items with my white-gloved hands, bring them to my nose for a whiff and place them on the pizza beside me.

After I'd plunked down a few slices and bulbs, a lawn mower drove by, unattended, sounding just like a lawn mower and spewing grass in my general direction. As the four-wheeled interloper receded, I pushed a red button to slide the pizza into the oven.

The visual and auditory elements of this surreal experience were amazing. I felt like I'd been transported onto the Holodeck in a "Star Trek" show. But most remarkable were the scents provided by OVR Technology garlic, cut grass, hot Italian pie that wafted toward my nose at just the right moments.

The first time OVR Technology CEO Aaron Wisniewski tried VR, "It kind of blew my mind," he told Seven Days. "I immediately was like, 'This is the future. This is so cool. There is so much that can be done with this. But the thing that's missing, the thing that would make it feel like a real experience, is what I specialize in, which is scent.'"

Unbeknownst to many, "Our sense of smell is the only one of our senses with a direct link to the memory and emotions section of our brain, the limbic system," Wisniewski said in a TEDx Talk recorded in Stowe last May. "Every time you have an experience, it's inextricably linked to the smell of that moment and stored in the memory banks that make us who we are."

He believes that olfactory virtual reality could serve many purposes, from enjoyable to life changing. It could enhance a meditation practice, train employees in a task, teach first responders greater resilience to stress, diagnose anosmia (a loss or impairment of the sense of smell) and deepen exposure therapy for vets with posttraumatic stress disorder.

OVR Technology's mission, Wisniewski said in an interview, "is to have real-world positive impacts by enhancing the virtual world through scent. It's not just a cool thing or a gimmick. We want outcomes and impacts that are measurable."

The company aims to improve health care, education and training, and its first product is a three-component platform called Architecture of Scent. One component is the small ION device, which straps onto a VR headset, close to the wearer's nose. ION contains the second component, nine cartridges that store and emit highly realistic scents created by the company, or "scentware." The third component is software that interacts with VR software to cue delivery of scents in precisely measured doses timed to correspond to the headset wearer's behavior.

The scent of a rose should "be more intense the closer you get to it," Stein said. "Or, if there's a wind blowing" in the VR environment, the software calibrates "how the wind carries that scent."

Wisniewski cofounded OVR Technology in 2017 with his brother Sam Wisniewski, company COO and CFO; Matt Flego, CTO; and Erik Cooper, head of design. The four met at Generator maker space in Burlington. There, the Wisniewski brothers founded Alice & the Magician Cocktail Apothecary, which sells edible elixirs and aromatic mists; and Flego and Cooper founded M//E Design, an industrial design and prototyping company.

The Wisniewskis still own Alice & the Magician, now located on Pine Street, but spend most of their time at OVR Technology. "A really talented operations manager takes care of the day-to-day" at Alice & the Magician, Aaron Wisniewski said.

Last June, Flego and Cooper closed M//E Design, which had designed such products as the popular Core 360 active seating chair, to focus exclusively on the new business.

In 2015, the four founders learned about VR from Kip Steele, technical leader at Asure Software. Steele, who worked in information technology at the University of Vermont at the time, brought a headset to Generator.

About a year later, Champlain College started an experimental project to combine scents with VR. Faculty members invited Wisniewski to serve as a scent expert, and soon he and the other founders had created software, scentware and a prototype of the ION device.

"It looks like an elaborate mousetrap," Flego said of the prototype. At the proof of concept a successful demonstration of the olfactory virtual reality technology "we impressed some people, got a little bit of traction and a little bit of money," he recalled. Wisniewski was convinced that the product had huge potential, and soon his brother, Flego and Cooper joined him in creating OVR Technology.

A key collaborator who has helped guide development of the Architecture of Scent is Albert "Skip" Rizzo, a research professor at the University of Southern California and director for medical virtual reality at USC's Institute for Creative Technologies. He researches the use of VR to assess, treat, rehabilitate and increase resilience in psychology patients. Rizzo received the American Psychological Association's 2010 Award for Outstanding Contributions to the Treatment of Trauma for his work using virtual reality-based exposure therapy to treat PTSD.

Rizzo "has a deep understanding of how scents are an integral piece of the puzzle of PTSD," Wisniewski said. "We've been working closely with him and getting feedback from him on what types of scents to develop and how our technology can be effective with exposure therapy."

Rizzo is currently perfecting his Bravemind VR program for vets with PTSD and plans to distribute it to more than 100 VA hospitals around the country. OVR Technology is developing combat-related scents to enhance Bravemind.

Closer to home, OVR Technology is collaborating with David Lg Tomasi, who teaches and conducts research in the UVM Integrative Health program and Larner College of Medicine. He's also a clinical psychologist and psychotherapist at the UVM Medical Center.

"There is a lot of neuroscientific evidence of the role that sensory activation plays in our brain for general well-being," Tomasi said, "and by that I mean either in the stimulation of the olfactory bulb or the virtual-reality type of strategy."

Just as people can trick their brains into stimulating salivation by thinking about sucking on a lemon, he explained, VR can trick the brain into releasing neurotransmitters that are specifically focused on well-being.

"What is brand new is this combination" of olfactory stimulation and virtual reality, Tomasi emphasized.

"We've been doing integrative medicine for years on the patient psychiatry unit, mostly focusing on dietary examples, exercise, meditation, art therapy," he continued. But some patients can't participate due to medical issues, and Tomasi believes OVR Technology's product could help reduce their pain, stress and anxiety.

Not all olfactory virtual reality scenarios are as wacky or surreal as the pizza-with-lawn-mower demo I experienced. Tomasi found OVR Technology's woods-like demo so realistic that it was "really peaceful and nurturing. You could walk around, see the trees, see the landscape, the leaves and stones and rocks. You could pick up a marshmallow to roast, and you could have some water."

Sometimes, users forget that they're not in the real world. "Early on, we had a demo with a picnic table in it," Wisniewski recalled. "People would become so immersed in the environment that, within a minute or two, they would try to lean on the picnic table and fall over." After seeing a couple of people "hit the deck," the company adjusted the demo to keep people safe.

Within the next month or so, Tomasi and OVR Technology will launch a pilot study to collect qualitative and quantitative data from 12 volunteer UVM Medical Center inpatient subjects on the therapeutic value of olfactory virtual reality. A lot of research went into the study, which the team is confident is the first of its kind worldwide in a psychiatric setting. "It is groundbreaking research," Tomasi enthused.

A few other companies are also developing olfactory virtual reality, but OVR Technology's current challenges stem from more immediate concerns than competition. Because the VR industry is evolving quickly toward faster and smaller headsets, the company is already designing a smaller version of the ION device. It's also creating a "volume knob" to allow users to control the strength of scents delivered by the device.

Truth be told, I had a hard time smelling the tomato, basil and grass clippings in the demonstration. Though my brother's nose made him a successful New York City sommelier, my sniffer thinks Bayley Hazen Blue is a lot like Brie left in the fridge too long. I'd have welcomed a way to control the scent intensity, as would others who've experienced OVR Technology demos, Flego said.

"It's a lot like hearing: Different people hear different frequencies, and there are tons of factors that degrade over time," Stein noted.

But the company is determined to make its technology seamless. In the long term, "we envision that the relationship between smell and virtual reality will become as ubiquitous as sound and television," Wisniewski said.

His commitment to this goal stems in part from a cautionary concern. Culturally, we have deprioritized our sense of smell and sanitized our environment to include fewer scents, Wisniewski noted. He cited research showing that anosmia can lead to depression, anxiety and physical harm.

"If we continue down the path of being glued to screens and virtual reality, while ignoring this extremely important primal sense that has been refined over millions of years, the implications are kind of alarming," he said. "We don't have that many senses. You take away one, and I don't see it going well."

Original post:
OVR Technology Is Creating Olfactory Virtual Reality for Health Care, Education and Training - Seven Days

Read More...

Change Of Weather May Have Increased Congestion: Try These 4 Home Remedies For Immediate Relief – Doctor NDTV

January 17th, 2020 10:48 am

Congestion home remedies: From ginger to honey, carrots and cardamom, there are many remedies that can offer relief from cough, cold and increased congestion. Read here to know all about them. HIGHLIGHTS

Congestion home remedies: The rains have delayed the respite from cold weather that Delhiites may have been expecting this time around. Coughing, cold, congestion and sneezing may have increased for some of you. This is the right time to take some precautionary measures if you want to prevent your condition from getting worse. The most important thing to do is wear appropriate clothes and keep yourselves covered with warm clothes. Wear a muffler, cap, gloves, socks, jacket and everything else that will offer protection from the cold weather.

Besides, there are a few home remedies that can help in reducing congestion because of cold weather. Lifestyle coach Luke Coutinho shares a few of them on Instagram.

Ginger contains anti-inflammatory properties that can be beneficial for you in more ways than one. It can help in reducing congestion and clearing nasal passages. To make ginger tea, mash a piece of ginger (fresh ginger). Add 3 black pepper corns, a pinch of cinnamon, some cardamom, and 3 mashed garlic cloves. Boil all the ingredients well in a glass of water and reduce it to half. Add a tsp of honey to sweeten this infused tea. According to Luke, this tea "works the best" for reducing congestion, cold, cough, sneezing and other symptoms that worsen in the cold weather.

Ginger can offer relief from cough and cold during change of weatherPhoto Credit: iStock

Also read:Ginger For Congestion: Know How It Works And Ways To Use Ginger For Reducing Cough, Cold And Congestion

Carrots are a rich source of Vitamin C, the immunity-boosting vitamin which can help in fighting colds, allergies and sinus infections. Carrots also contain Vitamin A, which can help in keeping your mucous membranes healthy. Eating carrots, winter squash and sweet potatoes can provide you with beta carotene which your body converts into Vitamin A. Coconut oil, on the other hand, can help in dealing with irritated or sore nose, which often occurs after a few days of suffering from cold. Prepare carrot juice with fresh carrots and add 1 tbsp of raw coconut oil to deal with increased congestion because of change in weather.

Also read:Speed Up Your Weight Loss Process With Carrots This Winter; Know Other Health Benefits

Blocked nose, sinus infection and congestion can be effectively curbed with the help of steam inhalation. Luke suggests adding 1 tbsp of ajwain to the steam water. Inhale it for 5 minutes and it can help in breaking down of mucous, he says.

Honey can be helpful in offering relief from cold and congestion. You can prepare a lemon infused tea and add 2 tsp honey to it. Honey can soothe you while lemon juice in hot water can reduce congestion.

Honey can offer relief from cough and sore throatPhoto Credit: iStock

Also read:Surprising Benefits Of Honey For Weight Loss, Wound Healing And Much More

(Luke Coutinho, Holistic Lifestyle Coach - Integrative Medicine)

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

Go here to read the rest:
Change Of Weather May Have Increased Congestion: Try These 4 Home Remedies For Immediate Relief - Doctor NDTV

Read More...

Page 752«..1020..751752753754..760770..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick